TSC2 and non-small cell lung carcinoma: Studies focus on STK11/LKB1 mutations with the immune microenvironment of NSCLC harboring KRAS mutations, and the impact of TSC1/TSC2 deficiency on immune checkpoint blockade in NSCLC (27–29).